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Up-regulation of cytokines and cell adhesion molecules by proinflammatory cytokines in vascular endothelial 
cells (ECs) represents part of the inflammatory process affecting vascular walls. To inhibit the expression of 
these inflammatory molecules is therefore one of the targets of anti-inflammatory drugs. The antiｭ
inflammatory action of glucocorticoids is mediated partly by the inhibition of the expression of several cytokines 
and adhesion molecules via glucocorticoid receptor (GR). Some other nuclear receptor activators have also been 
sbown to inhibit the expression of these inflammatrory molecules, although their molecular mechanisms remain 
unidentified. We therefore compared the effects ofthe pharmacological activators ofPPARαandGRon TNFα­
induced expression of IL-6 and VCAM-1 both of which promoters contain binding sites for NF-κB transcription 
factors that have key roles in inflammation. 
〔方法ならびに成績〕
Human umbilical vein endothelial cells (HUVECs) and bovine aortic endothelial cells (BAECs) were used. 
ECs were stimulated for IL-6 and VCAM -1production with TNFαafter pretreated with or without ligands for 
GR， PPARαandPPARγrespectively. 
Immunfluorescence studies were performed to reveal the cellular localization of GR and PPARα. In the 
absence of the ligand, PP ARαwas localized predominantly to the cytoplasm in HUVECs. When the cells were 
treated with the PP ARαactivator fenofibrate , PP ARαstaining was observed in the nuclei. In contrast, GR 
was localized in the nuclei of the cells regardless of whether the cells were treated with GR activator 
dexamethasone. 
Effects of fenofibrate and dexamethasone on IL-6 secretion and cell surface VCAM-1 expression induced by 
TNFαin the HUVECs were determined by ELISA. When HUVECs were treated with TNFα， the IL-6 
円。Aせ
concentration in the culture supernatants was increased to about 3-fold. TNFα-induced IL-6 production was 
inhibited by fenofibrate in a concentration-dependent manner, whereas it was not apparently inhibited by the 
PPARγactivator pioglitazone. Dexamethasone also showed significant inhibition of TNFα・induced IL-6 
production in a concentration-dependent manner, and this effect could be blocked by the GR antagonist RU486. 
Fenofibrate inhibited TNFα-induced cel surface VCAM-1 expression in a concentration-dependent manner in 
HUVECs. Whereas, dexamethasone had no effect on the TNFα-induced VCAM -1expression. 
Transient transfection assays showed that fenofibrate significantly inhibited TNFα-induced IL-6 and VCAM-1 
promoter activities. Meanwhile, in GR expression vector transfected BAECs, dexamethasone significantly 
inhibited the TNFα-induced IL-6 promoter activity, but failed to inhibit the TNFα-induced VCAM-1 promoter 
activity. 
To investigate whether fenofibrate and dexamethasone affect NF-κB binding to its recognition sites in IL-6 as 
well as VCAM-1 promoters, EMSAs were performed. The TNFα-induced NF-κB complexes consisted mainly of 
p65 and p50. Both fenofibrate and dexamethasone suppressed TNFα-activated NF-κB binding to the 
oligonucleotide probe derived from human IL-6 gene promoter. By contrast, only fenofibrate inhibited TNFα­
activated NF-κB binding to the oligonucleotide probe from human VCAM-1 gene promoter. Pioglitazone 
elicited no effect on the NF-κB binding to the both oligonucleotide probes. 
Immunostaining studies indicated that neither fenofibrate nor dexamethasone could prevent TNFα-induced 
nuclear translocation of NF-κB. 
〔総括〕
Down-regulation of nuclear factor-κB activity by PP ARαoccurs in both the IL-6 and VCAM-1 genes, whereas 
that by GR occurs only in the IL-6 gene in vascular endothelial cels. This strongly suggests the existence of a 
target gene-specific mechanism for the nuclear receptor-mediated down-regulation of NF-κB activity. And, 
PPARαactivator may have the potential to relieve vascular inflammation. 
論文審査の結果の要旨
炎症によって惹起される遺伝子の多くは、核内転写因子 NF-κB によってその発現が促進される。グルココルチコ
イドが抗炎症作用を発揮するメカニズムの分子基盤として、グルココルチコイドレセプター (GR) が NF-κB の活性
を抑制し、炎症性遺伝子の発現を転写レベルで抑制することが報告されている。しかしグルココルチコイドが NF­
κB によって促進される全ての炎症性遺伝子の発現を一様に抑制するわけではなく、その分子機構は不明である。本
研究は、血管内皮細胞における IL-6 と VCAM-1 の発現に対する、 GR と Peroxisomeproliferator-activated receptor 
α(PPARα) の作用について解析したものである。本研究により、 IL-6 ・ VCAM-1 の発現に対して GR と PPARα
が特異的な制御を示すこと、そしてその制御の特異性は NF-κB の転写活性および、遺伝子のプロモ}ター活性のレベ
ルで認められることが示された。このことは、同じ NF-κB により誘導される遺伝子で、あっても、 NF-κB の活性に対
する 2 種の核内受容体の抑制作用が異なることを示した新しい知見である。本知見は、抗炎症薬がなぜ特定の炎症性
遺伝子の発現のみを抑制し得るか、という疑問に対する一つの回答を示したものであり、特定の遺伝子をターゲット
とした抗炎症薬の開発にも繋がるものであり、学位の授与に値するものと考えられる。
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